# APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

> **NCT04419389** · PHASE1,PHASE2 · TERMINATED · sponsor: **Aprea Therapeutics** · enrollment: 1 (actual)

## Conditions studied

- Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** APR-246 (eprenetapopt) + Acalabrutinib in CLL
- **DRUG:** APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL
- **DRUG:** APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT
- **DRUG:** APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT

## Key facts

- **NCT ID:** NCT04419389
- **Lead sponsor:** Aprea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-02
- **Primary completion:** 2021-08-23
- **Final completion:** 2021-08-24
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04419389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04419389, "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04419389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*